CELL INTELLIGENCE · 肿瘤细胞治疗研究

Claudin 18.2 靶向：泛癌视角

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Claudin-6 作为卵巢癌治疗的潜在靶点：新兴药物综述

Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs.

Claudin-6 靶向治疗为复发性或铂耐药卵巢癌患者代表了一种有前景的进展。在当前的方法中，ADC 由于其效力和可控的安全性特征，似乎最接近广泛的临床适用性。未来的成功将取决于标准化的诊断检测、生物标志物驱动的试验设计以及合理的联合策略，以克服耐药性并最大化持久的临床获益。

卵巢癌免疫治疗进展

Advances in immunotherapies in ovarian cancer.

卵巢癌中叶酸受体-α 靶向治疗：最新进展与新兴治疗策略

Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies.

仿生氧化 mRNA 脂质纳米颗粒用于体外工程化靶向实体瘤的嵌合抗原受体巨噬细胞

Bioinspired oxidized mRNA lipid nanoparticles for ex vivo engineering of chimeric antigen receptor macrophages targeting solid tumors.

用代谢物感知受体工程化 NK 和 T 细胞以靶向实体瘤

Engineering NK and T cells with metabolite-sensing receptors to target solid tumors.

工程化改造 CAR-T 细胞分泌 VEGF 中和 scFv 增强对实体瘤的抗肿瘤活性

Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors.

高内涵 SRS 成像揭示 CAR-T 治疗下卵巢癌中胆固醇代谢改变

High-Content SRS Imaging Unveils Altered Cholesterol Metabolism in Ovarian Cancers Under CAR-T Treatment.

靶向间皮素的全人源嵌合抗原受体自体 T 细胞在表达间皮素的癌症中的 1 期研究

Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.

工程化转基因尺寸超越现有局限的单载体逻辑门控 CAR-T 细胞

Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.

这些数据建立了工程化逻辑门控单载体免疫疗法的框架，并提供了生成携带超出当前尺寸限制转基因的 CAR-T 细胞的优化工作流程。